Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

AstraZeneca, Penn Medicine in Alzheimer’s disease therapy deal
May 2010
SHARING OPTIONS:

PHILADELPHIA—The University of Pennsylvania's Penn Medicine's Center for Neurodegenerative Disease Research (CNDR) and AstraZeneca have signed a collaborative research agreement focused on generating new Alzheimer's disease (AD) drug candidates for the clinical development pipeline. CNDR will provide access to drug compound screening assays and expertise with the protein tau. AstraZeneca scientists will supply basic drug discovery research and technologies. The agreement contains potential royalties and milestone payments linked to successful clinical development and eventual worldwide marketing of tau-targeted therapies for Alzheimer's disease. AstraZeneca has exclusive access to compound IP and study data for any commercial purposes. Specific financial details were not disclosed. 

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.